Insider transaction details
Minang Turakhia, Chief Medical Officer of iRhythm Holdings (NASDAQ: IRTC), sold 7,804 shares of the company's common stock on February 25, 2026, at a price of $135.42 per share, for a total proceed of approximately $1.05 million. The sale is recorded amid a recent stretch of share-price weakness - the stock declined 11.8% over the past week before trading higher to $140.06.
Concurrent RSU conversion
According to a Form 4 filing with the Securities and Exchange Commission, Turakhia also received 15,060 shares of common stock on February 24, 2026, at no cost. Those shares were issued upon satisfaction of performance conditions tied to previously granted performance Restricted Stock Units (RSUs).
Post-transaction holdings
After the sale and the issuance, Turakhia directly holds 48,899 shares of iRhythm Holdings common stock, as reflected in the filing.
Valuation context
InvestingPro analysis referenced with the filings indicates that iRhythm's shares currently look overvalued relative to its Fair Value estimate. For investors wanting deeper insight into insider transactions and broader equity analysis, InvestingPro provides a Pro Research Report on IRTC, one of more than 1,400 U.S. equities covered by its research platform.
Company operating results and outlook
iRhythm Technologies reported fourth-quarter revenue of $208.9 million, a 27.1% increase year-over-year, topping early estimates of more than $201.8 million. The company also reported positive GAAP net income for the first time and an adjusted EBITDA of $34.3 million. Management cited record revenue unit volume in the fourth quarter as a contributor to exceeding its 2025 revenue guidance.
For 2026, iRhythm projects revenue growth of 17% to 18%, translating into expected revenue between $870 million and $880 million. The company also forecasts an adjusted EBITDA margin of roughly 11.5% to 12.5% for the year.
Analyst reactions
Analysts at Truist Securities and Canaccord Genuity reduced their price targets for iRhythm Technologies to $200 and $198, respectively, while keeping Buy ratings. Morgan Stanley reiterated an Overweight rating with a $205 price target, noting the company’s strong preliminary fourth-quarter performance.
This report compiles reported insider activity, company results and analyst actions as disclosed in regulatory filings and company announcements.